-

PRCH Stockholders: Robbins LLP Reminds Investors it is Investigating the Officers and Directors of Porch Group, Inc.

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP is investigating Porch Group, Inc. (NASDAQ: PRCH) to determine whether certain Porch Group officers and directors violated securities laws and breached fiduciary duties to shareholders by engaging in a conflicted SPAC process. In December 2020, special purpose acquisition company PropTech Acquisition Corp. (PTAC) completed a business combination with Porch.com, after which the Company proceeded to operate as Porch Group, Inc. At its height, Porch Group shares traded over $27.00 per share. Today, the shares trade under $1.00.

What Now: Porch Group, Inc. shareholders have legal options. If you owned shares of PropTech Acquisition Corp. at the time of the business combination and have incurred significant loss in the stock, contact us for more information about your rights.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Contact us to learn more:

Aaron Dumas, Jr.
(800) 350-6003
adumas@robbinsllp.com
Shareholder Information Form

About Robbins LLP: Some law firms issuing releases about this matter do not actually litigate securities class actions; Robbins LLP does. A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. Since our inception, we have obtained over $1 billion for shareholders.

To be notified if a class action against Porch Group, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Robbins LLP

NASDAQ:PRCH

Release Summary
Robbins LLP Reminds Investors it is Investigating the Officers and Directors of Porch Group, Inc.
Release Versions
$Cashtags

Contacts

Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Social Media Profiles
More News From Robbins LLP

Robbins LLP Informs Stockholders it is Investigating Potential Securities Claims Involving Wealthfront Corporation

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP is investigating Wealthfront Corporation (NASDAQ: WLTH) to determine whether certain Wealthfront officers and directors violated securities laws and breached fiduciary duties to shareholders.Why Are We Investigating Wealthfront?Wealthfront completed its initial public offering in December 2025, offering 34,615,384 shares of common stock at $14.00 per share, including shares sold by the Company and selling stockholders. The Compa...

Robbins LLP Informs Stockholders It Is Investigating Potential Securities Claims Involving Hyliion Holdings Corp.

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP is investigating Hyliion Holdings Corp. (AMEX: HYLN) to determine whether certain Hyliion Holdings officers and directors violated securities laws and breached fiduciary duties to shareholders. Hyliion is a power generator company whose primary product is the KARNQ Power Module.Why Are We Investigating Hyliion Holdings?Hyliion stock dropped 16% on Tuesday, June 23, 2026, following the release of a short-seller report from Pelica...

Robbins LLP Urges CAPR Stockholders to Contact the Firm for Information About the Class Action Against Capricor Therapeutics, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs investors that a securities class action has been filed on behalf of all persons and entities that purchased or otherwise acquired Capricor Therapeutics, Inc. (NASDAQ: CAPR) securities between December 17, 2025 and July 26, 2026 (the "Class Period").The lawsuit alleges that Capricor Therapeutics misled investors regarding the path to FDA approval for its lead product candidate Deramiocel, a cell therapy to address cardiac and skeletal muscle compli...
Back to Newsroom